Mouse strain differences in phencyclidine-induced behavioural changes

International Journal of Neuropsychopharmacology

Volumn 15, Issue 6, 2012, Pages 767-779

  Mouri, Akihiro ^a,b   Koseki, Takenao ^a   Narusawa, Shiho ^a   Niwa, Minae ^a,c,d   Mamiya, Takayoshi ^a   Kano, Shin Ichi ^d   Sawa, Akira ^d   Nabeshima, Toshitaka ^a  

^a MEIJO UNIVERSITY   (Japan)

^b Japanese Society of Pharmacopoeia   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavioural sensitization; forced swim test; mouse strain difference; phencyclidine; schizophrenia

Indexed keywords

PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; C57BL 6 MOUSE; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOPHENOTYPE; FORCED SWIM TEST; FUNCTION TEST; GENETIC IDENTIFICATION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HYPERLOCOMOTION; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOGNITION; SCHIZOPHRENIA; STRAIN DIFFERENCE; TOXICOGENETICS;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, OUTBRED STRAINS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FRONTAL LOBE; HALLUCINOGENS; HYPERKINESIS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MOTOR ACTIVITY; PHENCYCLIDINE; SPECIES SPECIFICITY; SWIMMING; TIME FACTORS;

EID: 84862142530     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571100085X     Document Type: Article

References (49)

1. Abdel-Naby Sayed M, Noda Y, Mahmoud Hamdy M, Mamiya T, et al. (2001). Enhancement of immobility induced by repeated phencyclidine injection : association with c-Fos protein in the mouse brain. Behavioural Brain Research 124, 71-76. (Pubitemid 32567560)
2. Almond SL, Fradley RL, Armstrong EJ, Heavens RB, et al. (2006). Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Molecular and Cellular Neurosciences 32, 324-334. (Pubitemid 44163228)
3. Balla A, Koneru R, Smiley J, Sershen H, et al. (2001). Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25, 157-164. (Pubitemid 32566337)
4. Beraki S, Diaz-Heijtz R, Tai F, Ogren SO (2009). Effects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice. International Journal of Neuropsychopharmacology 12, 243-255.
5. Beraki S, Kuzmin A, Tai F, Ogren SO (2008). Repeated low dose of phencyclidine administration impairs spatial learning in mice: blockade by clozapine but not by haloperidol. European Neuropsychopharmacology 18, 486-497.
6. Corso TD, Sesma MA, Tenkova TI, Der TC, et al. (1997). Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Research 752, 1-14. (Pubitemid 27143892)
7. Desbonnet L, Waddington JL, Tuathaigh CM (2009). Mice mutant for genes associated with schizophrenia : common phenotype or distinct endophenotypes? Behavioural Brain Research 204, 258-273.
8. Deutsch SI, Rosse RB, Paul SM, Riggs RL, et al. (1997). Inbred mouse strains differ in sensitivity to 'popping' behavior elicited by MK-801. Pharmacology, Biochemistry and Behavior 57, 315-317. (Pubitemid 27261427)
9. Fatemi SH, Folsom TD (2009). The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophrenia Bulletin 35, 528-548.
10. Flint J, Shifman S (2008). Animal models of psychiatric disease. Current Opinion in Genetics and Development 18, 235-240.
11. Glessner JT, Hakonarson H (2009). Common variants in polygenic schizophrenia. Genome Biol 10, 236.
12. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, et al. (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. European Neuropsychopharmacology 18, 448-454.
13. Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. European Journal of Pharmacology 519, 114-117. (Pubitemid 43181173)
14. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, et al. (2007). Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proceedings of the National Academy of Sciences USA 104, 14501-14506. (Pubitemid 350003290)
15. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
16. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine : from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225. (Pubitemid 29067401)
17. Jentsch JD, Taylor JR, Roth RH (1998). Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress-and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19, 105-113. (Pubitemid 28288436)
18. Jentsch JD, Tran A, Le D, Youngren KD, et al. (1997). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17, 92-99.
19. Konno R, Yasumura Y (1983). Mouse mutant deficient in D-amino acid oxidase activity. Genetics 103, 277-285. (Pubitemid 13147202)
20. Kunitachi S, Fujita Y, Ishima T, Kohno M, et al. (2009). Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Research 1279, 189-196.
21. Li N, Lee B, Liu RJ, Banasr M, et al. (2010). mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
22. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, et al. (1959). Study of a new schizophrenomimetic drug; sernyl. AMA Archives of Neurology and Psychiatry 81, 363-369.
23. Maddox VH, Godefroi EF, Parcell RF (1965). The synthesis of phencyclidine and other 1-arylcyclohexylamines. Journal of Medicinal Chemistry 8, 230-235.
24. Maeng S, Zarate CA, Du J, Schloesser RJ, et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine : role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 63, 349-352. (Pubitemid 351146651)
25. Mekada K, Abe K, Murakami A, Nakamura S, et al. (2009). Genetic differences among C57BL/6 substrains. Experimental Animals 58, 141-149.
26. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436. (Pubitemid 29402481)
27. Molteni R, Pasini M, Moraschi S, Gennarelli M, et al. (2008). Reduced activation of intracellular signaling pathways in rat prefrontal cortex after chronic phencyclidine administration. Pharmacological Research 57, 296-302.
28. Mouri A, Noda Y, Enomoto T, Nabeshima T (2007a). Phencyclidine animal models of schizophrenia : approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochemistry International 51, 173-184. (Pubitemid 47176714)
29. Mouri A, Noda Y, Noda A, Nakamura T, et al. (2007b). Involvement of a dysfunctional dopamine-D1/N-methyld-aspartate-NR1 and Ca2 +calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Molecular Pharmacology 71, 1598-1609. (Pubitemid 47010913)
30. Murai R, Noda Y, Matsui K, Kamei H, et al. (2007). Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: implications for abnormalities of glutamate release and NMDA-CaMKII signaling. Behavioural Brain Research 180, 152-160. (Pubitemid 46719421)
31. Nabeshima T, Fukaya H, Kamei H, Ishikawa K, et al. (1989a). Cross sensitization between phencyclidine and methamphetamine: I repeated administration of methamphetamine at a low dose. Research Communications in Substances of Abuse 10, 62-76. (Pubitemid 19053591)
32. Nabeshima T, Fukaya H, Kamei H, Ishikawa K, et al. (1989b). Cross sensitization between phencyclidine and methamphetamine: II repeated administration of methamphetamine at a high dose. Research Communications in Substances of Abuse 10, 95-107. (Pubitemid 19203965)
33. Nabeshima T, Fukaya H, Yamaguchi K, Ishikawa K, et al. (1987). Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. European Journal of Pharmacology 135, 23-33. (Pubitemid 17051006)
34. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, et al. (1986). Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats. Neuroscience Letters 69, 275-278. (Pubitemid 16012091)
35. Nagai T, Murai R, Matsui K, Kamei H, et al. (2009). Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 202, 315-328.
36. Nagai T, Noda Y, Une T, Furukawa K, et al. (2003). Effect of AD-5423 on animal models of schizophrenia : phencyclidine-induced behavioral changes in mice. Neuroreport 14, 269-272. (Pubitemid 36308425)
37. Noda Y, Mamiya T, Furukawa H, Nabeshima T (1997). Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. European Journal of Pharmacology 324, 135-140. (Pubitemid 27174597)
38. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine : a new model of schizophrenia. British Journal of Pharmacology 116, 2531-2537.
39. Olivier B, Leahy C, Mullen T, Paylor R, et al. (2001). The DBA/2J strain and prepulse inhibition of startle : a model system to test antipsychotics? Psychopharmacology 156, 284-290. (Pubitemid 32702219)
40. Olney JW, Labruyere J, Price MT (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360-1362. (Pubitemid 19170513)
41. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 33, 523-533.
42. Otte DM, Bilkei-Gorzo A, Filiou MD, Turck CW, et al. (2009). Behavioral changes in G72/G30 transgenic mice. European Neuropsychopharmacology 19, 339-348.
43. Perera PY, Lichy JH, Mastropaolo J, Rosse RB, et al. (2008). Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist. European Neuropsychopharmacology 18, 814-819.
44. Pletnikov MV (2009). Inducible and conditional transgenic mouse models of schizophrenia. Progress in Brain Research 179, 35-47.
45. Popik P, Kos T, Sowa-Kucma M, Nowak G (2008). Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berlin) 198, 421-430.
46. Popova NK, Naumenko VS, Tibeikina MA, Kulikov AV (2009). Serotonin transporter, 5-HT1A receptor, and behavior in DBA/2J mice in comparison with four inbred mouse strains. Journal of Neuroscience Research 87, 3649-3657.
47. Porsolt RD, Le Pichon M, JalfreM(1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730-732. (Pubitemid 8073804)
48. Schell MJ (2004). The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 359, 943-964. (Pubitemid 38784082)
49. Snyder SH (1988). Psychotogenic drugs as models for schizophrenia. Neuropsychopharmacology 1, 197-199.